Teva Pharma Posts Profit In Q2, Adj. EPS Beats Market, While Revenues Miss; Lifts FY25 Earnings View

Teva Pharmaceutical Industries

13.09 CHF -11.20%

• Charts
• News
• Analysen

Kaufen Verkaufen

(RTTNews) - Teva Pharmaceutical Industries Ltd (TEVA) reported Wednesday a profit in its second quarter, compared to prior year's loss, with slightly higher net revenues. Adjusted earnings beat market estimates, while top line missed the view.

Further, the company raised the lower end of its fiscal 2025 adjusted earnings outlook range, and maintained revenue view. The company added that it is on track for 30 percent operating profit margin by 2027 in line with Pivot to Growth Strategy.

In the pre-market activity, Teva shares were losing around 2 percent to trade at $16.21.

For fiscal 2025, the company now projects adjusted earnings in a range of $2.50 to $2.65 per share, a growth of $0.05 at the low-end of its previous outlook range of $2.45 to $2.65 per share.

Further, the company continues to expect revenues between $16.8 billion and $17.2 billion.

On average, analysts polled expect the company to report earnings of $2.53 per share on revenues of $16.92 billion for the year. Analysts' estimates typically exclude special items.

In the second quarter, net income attributable to Teva was $282 million, compared to prior year's loss of $846 million. Earnings per share were $0.24, compared to loss of $0.75 per share a year ago.

Adjusted net earnings were $769 million or $0.66 per share, compared to $697 million or $0.61 per share a year ago. Analysts expected earnings of $0.62 per share for the quarter.

Net revenues edged up to $4.176 billion from last year's $4.164 billion. The Street expected revenues of $4.27 billion for the quarter.

Revenues in the second quarter decreased 1 percent in local currency terms.

This decrease was mainly due to a decrease from generic products in International Markets segment associated with the divestment of business venture in Japan, as well as in U.S. segment.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.